Background: Irritable bowel syndrome refers to a subgroup of disorders of gut–brain interaction associated with stress-related symptoms, but gastrointestinal infection can also be considered the leading risk factor. It is well reported that coronavirus disease 2019 can also result in gastroenteritis. Therefore, this study aimed to evaluate the incidence of post-infectious irritable bowel syndrome and stressful status among coronavirus disease 2019 patients. Methods: This cross-sectional study was conducted on adults with coronavirus disease 2019 referred to the Infectious Disease Clinic in Iran from November 2020 to February 2021. Patients who met all eligibility criteria were included in the study. The data were collected using a demographic questionnaire, Rome IV criteria questionnaire, and Hospital Anxiety and Depression Scale. Results: Totally, the data obtained from 233 eligible patients (136 women, 97 men; mean age 38.41) 11.52 (years) were collected and analyzed, and 53.2% of the cases had a moderate coronavirus disease 2019. The analysis showed that 27 (11.6%) patients suffered from irritable bowel syndrome symptoms based on Rome IV criteria after the recovery from the infection. Also, Hospital Anxiety and Depression Scale-based symptoms of depression and anxiety that occurred with coronavirus disease 2019 were reported in 27.4% and 36.9%, respectively. Conclusion: Our finding illustrated that irritable bowel syndrome symptoms based on Rome IV could occur in post-infected coronavirus disease 2019 patients. Also, Hospital Anxiety and Depression Scale-based symptoms of depression and anxiety were more common in females and coronavirus disease 2019 infected patients with clinical symptoms including cough, shortness of breath, and sore throat.

No abstract

Background: Enteral immunomodulatory nutrition is recommended as an adjuvant therapy for patients in intensive care units (ICU), but its effectiveness is incompletely understood.Aim: The aim of this review was to examine the effect of a commonly used immunomodulatory formula-omega-3 fatty acids, γ-linolenic acid, and antioxidants-on clinical outcomes and mortality risk in critically ill patients.Design: Systematic review and meta-analysis of randomized controlled trials (RCTs).Method: PubMed, Scopus, and Institute for Scientific Information (ISI) Web of Knowledge databases were searched until 18 February 2021. RCTs that used the immunomodulatory formula in the ICU were included.Results: Ten RCTs (1166 participants) were included in the meta-analysis. The immunomodulatory formula reduced the duration of ICU stay weighted mean difference [(WMD): À2.

Objectives: Patients with coronavirus disease 2019 (COVID-19) can present anorexia and weight loss due to their symptoms and eating disorder which can lead to immune system weakness and increase the duration of recovery time. We aim to assess the severity and duration of anorexia and weight loss within the infection and recovery period in these patients. Method: We retrospectively identified 233 COVID-19 patients (older than 18 years) were admitted to the Rasoul-e Akram Hospital, from August to December 2020. Their medical records were reviewed by researchers. Then, patients who had inclusion criteria were asked about duration and severity of anorexia, and also weight alternation during the infection and after the recovery period.Result: Analyzed data were collected from 233 COVID-19 patients showed the mean duration of anorexia was 7.08 ± 10.41 days with a significant loss of appetite (-75.55 ± 88.09, P-value < 0.001

Enteral immunomodulatory nutrition is suggested as an adjuvant therapy for patients admitted in intensive care units (ICU), but its effectiveness remains debated. The aim of this systematic review and meta-analysis is to examine the effect of dietary immunomodulatory formula on the clinical outcomes and risk of overall mortality in critically ill patients. PubMed, Scopus and ISI web of Knowledge databases were searched until September 2019. Randomized Controlled Trials (RCTs) that used immunomodulatory diet containing omega-3 fatty acid, γ-linolenic acid and antioxidants in ICU were included. Ten RCTs including 1166 participants were included in the meta-analysis. Immunomodulatory diet containing omega-3 fatty acid, γlinolenic acid and antioxidants led to significantly reduce the duration of ICU stays (WMD:-2.97 days; 95%CI:-5.59,-0.35), duration of mechanical ventilation (WMD =-2.20 days, 95%CI:-4.29,-0.10), SOFA (sequential organ failure assessment) and MOD (multiple organ dysfunction) score (Hedge's g:-0.42 U/L; 95% CI:-0.74,-0.11). The 28 days' overall mortality was remarkably decreased following Immunomodulatory supplement in critically ill patients (RR = 0.74, 95% CI: 0.58, 0.91) and extended the ICU-free days (WMD: 4.06 days, 95%CI: 0.02, 8.09). However, immunomodulatory formula had no significant effect on length of hospital stays, ventilator-free days and level of oxygenation.Immunomodulatory diet containing omega-3 fatty acid, γ-linolenic acid and antioxidants might have beneficial effects for the patient's residing in ICU; However, further well-designed RCTs with larger sample size are recommended to confirmed its effect.